Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treatments."

"VTX-2337 provides unique abilities compared to other TLR agonists in clinical development, most notably a robust and highly selective activation of myeloid dendritic cells and natural killer cells," said Robert Hershberg, M.D., Ph.D., President and Chief Medical Officer of VentiRx. "These preclinical efficacy findings combined with the favorable safety profile of VTX-2337 established in the recently completed Phase 1 trial support the advancement of our broad clinical development program currently underway to evaluate the safety and efficacy of VTX-2337 in combination with standard of care cancer therapies."

VentiRx has advanced VTX-2337 into clinical trials designed to evaluate the compound in multiple oncology indications in combination with a variety of anticancer agents, including chemotherapy and monoclonal antibody therapy. Clinical trials of VTX-2337 currently underway include a combination study with chemotherapy in late stage ovarian cancer and a combination trial with cetuximab in head and neck cancer patients. In addition, a trial of VTX-2337 in combination with chemotherapy in metastatic breast cancer is targeted to begin in mid-2012.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. The Company's initial focus is on developing novel small molecule product candidates targeting Toll-based product candidates for oncology and allergy. VentiRx is a privately held organization with operations in Seattle. For additional information, please visit www.ventirx.com.

 

Contact:

Robert Hershberg, M.D., Ph.D.
President and Chief Medical Officer
VentiRx Pharmaceuticals, Inc.
(206) 689-2268
rhershberg@ventirx.com

Julie Rathbun
Rathbun Communications
(206) 769-9219
julie@rathbuncomm.com

 


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology:
(Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):